{"nctId":"NCT01438411","briefTitle":"Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis","startDateStruct":{"date":"2010-01"},"conditions":["Bile Acid Synthesis Defect"],"count":53,"armGroups":[{"label":"Cholic Acid","type":"OTHER","interventionNames":["Drug: Cholic Acid"]}],"interventions":[{"name":"Cholic Acid","otherNames":["Cholic","Cholic Acid Capsules"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nSubjects who received cholic acid through CCHMC protocols 91-10-10 or CAC-002-01 and meet the following criteria are eligible for study participation.\n\n1. The subject and/or parent/legal guardian must have provided informed consent prior to study start.\n2. The subject must have a diagnosis of an inborn error of bile acid synthesis.\n3. The subject must be willing and able to comply with all study assessments and procedures.\n4. Subjects with other organ dysfunction will not be excluded","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Atypical Urinary Bile Acid Excretion by FAB-MS (Fast-Atom-Bombardment Ionization-Mass Spectrometry)","description":"The level of atypical urinary bile acid secretion was scored using a scale of: 0, normal; 1, slight; 2, significant; or 3, marked. A Cochran-Mantel-Haenszel (CMH) test with modified ridit scoring was used to compare the difference between the score at baseline and the worst post-baseline score during treatment with cholic acid in this single-arm trial.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Evaluation of Serum Transaminases: ALT","description":"Changes in ALT were evaluated in terms of elevations above the upper limit of normal (ULN) and were categorized as: \\<ULN; ≥1 ULN but \\<2 ULN; ≥2 ULN but \\<3 ULN; and ≥3x ULN. Changes from baseline to the worst post-baseline value during treatment with cholic acid in this single-arm trial were presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Evaluation of Serum Transaminases: AST","description":"Changes in AST were evaluated in terms of elevations above the upper limit of normal (ULN) and were categorized as: \\<ULN; ≥1 ULN but \\<2 ULN; ≥2 ULN but \\<3 ULN; and ≥3x ULN. Changes from baseline to the worst post-baseline value during treatment with cholic acid in this single-arm trial were presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Results: Bilirubin","description":"Changes from baseline to the worst post-baseline value during treatment with cholic acid in this single-arm trial for bilirubin. Changes from baseline to the worst post-baseline value during treatment with cholic acid in this single-arm trial were presented in terms of descriptive statistics.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.678","spread":"1.1427"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.785","spread":"1.1464"}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Results: Gamma Glutamyl Transferase (GGT)","description":"Changes from baseline to the worst post-baseline value during treatment with cholic acid in this single-arm trial for GGT. Changes from baseline to the worst post-baseline value during treatment with cholic acid in this single-arm trial were presented in terms of descriptive statistics.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.8","spread":"7.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.4","spread":"8.28"}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Results: Alkaline Phosphatase","description":"Changes from baseline to the worst post-baseline value during treatment with cholic acid in this single-arm trial for alkaline phosphatase. Changes from baseline to the worst post-baseline value during treatment with cholic acid in this single-arm trial were presented in terms of descriptive statistics.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"293.7","spread":"30.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.6","spread":"17.71"}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Results: Prothrombin Time","description":"Changes from baseline to the worst post-baseline value during treatment with cholic acid in this single-arm trial for prothrombin time. Changes from baseline to the worst post-baseline value during treatment with cholic acid in this single-arm trial were presented in terms of descriptive statistics.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.977","spread":"2.1338"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.045","spread":"2.1442"}]}]}]},{"type":"SECONDARY","title":"Physical Examinations: Height","description":"Changes in height percentiles from baseline to the worst post-baseline value during treatment with cholic acid in this single-arm trial.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.767","spread":"4.4448"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.540","spread":"4.1064"}]}]}]},{"type":"SECONDARY","title":"Physical Examinations: Body Weight","description":"Changes in body weight percentiles from baseline to the worst post-baseline value during treatment with cholic acid in this single-arm trial.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.030","spread":"5.2853"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.227","spread":"4.9842"}]}]}]},{"type":"SECONDARY","title":"Incidence of Adverse Events","description":"Number (%) of patients with any AE","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":19,"n":53},"commonTop":["Upper respiratory tract infection","Abdominal pain","Diarrhoea","Vitamin D decreased","Nasopharyngitis"]}}}